@TumorBoardTues Looking forward to the discussion on #RET #precisionmedicine
@Aiims1742
@ShaalanBeg
@weoncologists
@RETpositive
@MPishvaian
@StephenVLiu
@DrSteveMartin
@marklewismd
@neerajaiims
@montypal
@ADesaiMD
@jacobadashek
@n8pennell
@VamsiVelcheti
@kyawzinthein86
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 A healthy 56-year-old man presents with neck swelling persisting after 2 weeks of antibiotics. No congenital anamoly. PPD negative. #TumorBoardTuesday
What would you do next ? @marklewismd @StephenVLiu
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 Work-up led to total thyroidectomy+ bilateral neck dissection, a diagnosis of #thyroidcancer with lymph node spread #TumorBoardTuesday @hemoncwarner @RenoHemonc @AMansfieldMD @VamsiVelcheti @kyawzinthein86
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba What do you suspect as diagnosis ⚕️? @AMansfieldMD @jacobadashek @ADesaiMD @PavlosMsaouel @jtmoyers #TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers Pathology revealed Medullary thyroid cancer. Germline testing was negative for RET mutation.
What molecular test will you order using the tumor tissue ? @jacobadashek @Aiims1742 @DralexGva @Alfdoc2 @weoncologists @RETpositive
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 NGS analysis of the resected tumor identified a RET M918T mutation. Additional imaging identified liver metastases. #TumorBoardTuesday @DrSteveMartin @kaushalpar @DrJNaidoo @StephenVLiu
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo He was sequentially treated with six multi-kinase inhibitor regimens: sorafenib [best response of progressive disease (PD)], vandetanib [stable disease (SD)], cabozantinib (SD), MGCD-516 (PD), RXDX-105 [partial response (PR)], & vandetanib+ everolimus (PD).
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo Each treatment was discontinued for disease progression in the liver, most recently with hepatomegaly, large-volume ascites, severe fatigue and markedly decreased performance status.
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo Here are the @myESMO ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research @DrSteveMartin @Annals_Oncology @curijoey @BenWestphalen annalsofoncology.org/article/S0923-…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Molecular analysis of cell-free DNA 🧪🧬 from blood 🩸taken before vandetanib + everolimus treatment identified the founder RET M918T mutation + a new RET V804M gatekeeper mutation @VamsiVelcheti .
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen What treatment would you start next ❓
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Patient was started on a selective RET inhibitor (Selpertcatinib or Pralsetinib). CEA and calcitonin levels decreased dramatically, together with resolution of diarrhea, abdominal pain and fatigue, 60 % response of target lesions #tumorboardtuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen New selective RET inhibitors ( Selpercatinib/ Pralsetinib) have activity and favourable toxicity profiles in RET-altered solid tumors #tumorboardtuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Mini-Tweetorial begins ! #tumorboardtuesday #RET #precisionmedicine
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen RET fusions are seen in NSCLC (2%) and papillary thyroid cancers (PTC; 10%–20%), whereas somatic (60%–90%) or germline (100%) RET mutations are seen in medullary thyroid cancer
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Advances in Targeting RET-Dependent Cancers @CD_AACR cancerdiscovery.aacrjournals.org/content/10/4/4…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR State-of-the-Art Strategies for Targeting RET-Dependent Cancers @ASCO_Pubs
#TumorBoardTuesday
ascopubs.org/doi/abs/10.120…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs Two selective RET inhibitors have been recently FDA approved for treatment RET altered thyroid and Lung cancers 👉Selpercatinib and Pralsetinib
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs Precision therapy for RET-altered cancers with RET inhibitors
#TumorBoardTuesday @CellPressNews
@trendscancer cell.com/trends/cancer/…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer Efficacy of Selpercatinib in RET-Altered Thyroid Cancers @NEJM
#TumorBoardTuesday
nejm.org/doi/full/10.10…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study @TheLancetEndo @AMansfieldMD
#TumorBoardTuesday
thelancet.com/journals/landi…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Both the newly approved RET inhibitor drugs have clinical activity against the gatekeeper RET V804 M mutation
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Selective RET kinase inhibition with selpercatinib for patients with RET-altered cancers @Annals_Oncology annalsofoncology.org/article/S0923-…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Precision Targeted Therapy with Pralsetinib or BLU-667 for RET-Driven Cancers @CD_AACR
#TumorBoardTuesday
cancerdiscovery.aacrjournals.org/content/8/7/836
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Over 40% of patients with RET-mutant Thyroidcancer on selpercatinib, reported clinical meaningful improvements in diarrhea Patient‐Reported Outcomes with Selpercatinib & RET‐Mutant Medullary Thyroid Cancer @OncJournal
#TumorBoardTuesday
theoncologist.onlinelibrary.wiley.com/doi/10.1002/on…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal RET alterations are seen in multiple cancer types and has the potential to be a tissue agnostic target @jacobadashek @ADesaiMD @andreevdrakhlin
#TumorBoardTuesday
mct.aacrjournals.org/content/early/…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers @jacobadashek @ADesaiMD @MCT_AACR mct.aacrjournals.org/content/early/…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer @NEJM
#TumorBoardTuesday
nejm.org/doi/full/10.10…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study @TheLancetOncol
#TumorBoardTuesday
thelancet.com/journals/lanon…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR @TheLancetOncol Tissue agnostic including Cholangiocarcinoma @curecc @MPishvaian 👉 Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
#TumorBoardTuesday
ascopubs.org/doi/abs/10.120…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR @TheLancetOncol @curecc Tissue agnostic including GI malignancies 👉Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers @MPishvaian @doctorpemm @weldeiry
#TumorBoardTuesday
cancerres.aacrjournals.org/content/81/13_…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR @TheLancetOncol @curecc @doctorpemm Broad-based genomic profiling is essential to identify actionable oncogenic drivers, including RET fusions
#TumorBoardTuesday @Dr_R_Kurzrock @JAMAOnc
jamanetwork.com/journals/jamao…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.